Top

Published in:

Open Access 01-04-2018 | Original Article

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Authors: Sofia E. Magnusson, Arwen F. Altenburg, Karin Lövgren Bengtsson, Fons Bosman, Rory D. de Vries, Guus F. Rimmelzwaan, Linda Stertman

Published in: Immunologic Research | Issue 2/2018

Abstract

Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuraminidase (NA). Various strategies to develop a vaccine that provides broad protection against different influenza A viruses are under investigation, including use of recombinant (r) viral vectors and adjuvants. The replication-deficient modified vaccinia virus Ankara (MVA) is a promising vaccine vector that efficiently induces B and T cell responses specific for the antigen of interest. It is assumed that live vaccine vectors do not require an adjuvant to be immunogenic as the vector already mediates recruitment and activation of immune cells. To address this topic, BALB/c mice were vaccinated with either protein- or rMVA-based HA influenza vaccines, formulated with or without the saponin-based Matrix-M™ adjuvant. Co-formulation with Matrix-M significantly increased HA vaccine immunogenicity, resulting in antigen-specific humoral and cellular immune responses comparable to those induced by unadjuvanted rMVA-HA. Of special interest, rMVA-HA immunogenicity was also enhanced by addition of Matrix-M, demonstrated by enhanced HA inhibition antibody titres and cellular immune responses. Matrix-M added to either protein- or rMVA-based HA vaccines mediated recruitment and activation of antigen-presenting cells and lymphocytes to the draining lymph node 24 and 48 h post-vaccination. Taken together, these results suggest that adjuvants can be used not only with protein-based vaccines but also in combination with rMVA to increase vaccine immunogenicity, which may be a step forward to generate new and more effective influenza vaccines.

Available only for authorised users

Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976–9. https://doi.org/10.1126/science.1244730.CrossRefPubMed

Westgeest KB, de Graaf M, Fourment M, Bestebroer TM, van Beek R, Spronken MI, et al. Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol. 2012;93(Pt 9):1996–2007. https://doi.org/10.1099/vir.0.043059-0.CrossRefPubMedPubMedCentral

Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, et al., editors. Fields virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1186–243.

World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003–2007. http://www.who.int/influenza/human_animal_interface/2017_07_25_tableH5N1.pdf?ua=1 Accessed: 25/09/2017. http://www.who.int/influenza/human_animal_interface/2017_07_25_tableH5N1.pdf?ua=1 Accessed 25/09/2017.

World Health Organization. Human infections with avian influenza A(H5N6) virus. http://www.who.int/csr/don/07-december-2016-ah5n6-china/en/. Accessed: 25/09/2017. Accessed 25/09/2017.

World Health Organization. Human infection with avian influenza A(H7N9) virus in China. http://www.who.int/csr/don/28-june-2017-ah7n9-china/en/. Accessed: 25/09/2017.

World Health Organization. WHO recommendations on the composition of influenza virus vaccines. http://www.who.int/influenza/vaccines/virus/recommendations/en/. Accessed: 24/09/2017.

Shaw ML, Palese P. Orthomyxoviridae. In: Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, et al., editors. Fields virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1151–85.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro surveill. 2015;20(4).

10.

Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro surveill. 2015;20(5):21025.CrossRefPubMed

11.

Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness—United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10–5.PubMedPubMedCentral

12.

Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, et al. Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014;6(7):2735–61. https://doi.org/10.3390/v6072735.CrossRefPubMedPubMedCentral

13.

de Vries RD, Rimmelzwaan GF. Viral vector-based influenza vaccines. Hum Vaccin Immunother. 2016;12(11):2881–901. https://doi.org/10.1080/21645515.2016.1210729.CrossRefPubMedPubMedCentral

14.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine. 2007;25(8):1513–25. https://doi.org/10.1016/j.vaccine.2006.10.047.CrossRefPubMed

15.

Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2(2):ofv040. https://doi.org/10.1093/ofid/ofv040.CrossRefPubMedPubMedCentral

16.

Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev Vacc. 2013;12(9):1095–108. https://doi.org/10.1586/14760584.2013.825445.CrossRef

17.

Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine. 2003;21(27–30):4234–7.CrossRefPubMed

18.

Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, et al. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J Infect Dis. 2016;214(11):1717–27. https://doi.org/10.1093/infdis/jiw414. CrossRefPubMedPubMedCentral

19.

Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine. 2009;28(1):171–8. https://doi.org/10.1016/j.vaccine.2009.09.103.CrossRefPubMed

20.

Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, et al. ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015;33(32):3953–62. https://doi.org/10.1016/j.vaccine.2015.06.047.CrossRefPubMed

21.

Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix-M adjuvant in a phase I clinical trial. Vaccine. 2011;29(45):8049–59. https://doi.org/10.1016/j.vaccine.2011.08.042.CrossRefPubMed

22.

Study of parenterally administrated adjuvanted seasonal influenza vaccine in healthy elderly volunteers. Identifier: NCT01444482.

23.

A(H7N9) VLP antigen dose-ranging study with Matrix-M1 adjuvant. Identifer: NCT02078674. [database on the Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02078674.

24.

Del Giudice G, Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol. 2015;386:151–80. https://doi.org/10.1007/82_2014_406. PubMed

25.

Osterhaus AD, Rimmelzwaan GF. Induction of virus-specific immunity by iscoms. Dev Biol Stand. 1998;92:49–58.PubMed

26.

Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B. 2007;8(3):153–61. https://doi.org/10.1631/jzus.2007.B0153.CrossRefPubMedPubMedCentral

27.

Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine. 2013;31(13):1725–33. https://doi.org/10.1016/j.vaccine.2013.01.039.CrossRefPubMed

28.

Reimer JM, Karlsson KH, Lovgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. 2012;7(7):e41451. https://doi.org/10.1371/journal.pone.0041451.CrossRefPubMedPubMedCentral

29.

Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses. 2011;5(6):426–37. https://doi.org/10.1111/j.1750-2659.2011.00256.x.CrossRefPubMedPubMedCentral

30.

Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine. 2009;27(52):7367–76. https://doi.org/10.1016/j.vaccine.2009.09.044.CrossRefPubMed

31.

Radosevic K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine. 2008;26(29–30):3640–6. https://doi.org/10.1016/j.vaccine.2008.04.071.CrossRefPubMed

32.

Cox F, Roos A, Hafkemeijer N, Baart M, Tolboom J, Dekking L, et al. Matrix-M adjuvated seasonal virosomal influenza vaccine induces partial protection in mice and ferrets against avian H5 and H7 challenge. PLoS One. 2015;10(9):e0135723. https://doi.org/10.1371/journal.pone.0135723.CrossRefPubMedPubMedCentral

33.

Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol. 2009;83(6):2540–52. https://doi.org/10.1128/JVI.01884-08.CrossRefPubMedPubMedCentral

34.

Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 2017;7:46621. https://doi.org/10.1038/srep46621.CrossRefPubMedPubMedCentral

35.

Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J. 2013;10:349. https://doi.org/10.1186/1743-422X-10-349.CrossRefPubMedPubMedCentral

36.

Lovgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem. 1988;10(2):161–72.PubMed

37.

Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis. 2007;195(11):1598–606. https://doi.org/10.1086/517614.CrossRefPubMed

38.

Palmer D.F. DWR, Coleman M.T. and Schild G.C. Advanced laboratory technicals for immunological diagnostics. In: Welfare USDHE, editor. Atlanta1975. p. 25–62.

39.

Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today. 1994;15(10):479–83. https://doi.org/10.1016/0167-5699(94)90193-7.CrossRefPubMed

40.

Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med. 1994;180(5):1841–7.CrossRefPubMed

41.

Bengtsson KL, Karlsson KH, Magnusson SE, Reimer JM, Stertman L. Matrix-M adjuvant: enhancing immune responses by ‘setting the stage’ for the antigen. Exp Rev Vacc. 2013;12(8):821–3. https://doi.org/10.1586/14760584.2013.814822.CrossRef

42.

Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510–2. https://doi.org/10.1126/science.1118948.CrossRefPubMed

43.

DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–51. https://doi.org/10.1038/nm.3443.CrossRefPubMedPubMedCentral

44.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016;34(16):1927–35. https://doi.org/10.1016/j.vaccine.2016.02.033.CrossRefPubMed

45.

Qu C, Brinck-Jensen NS, Zang M, Chen K. Monocyte-derived dendritic cells: targets as potent antigen-presenting cells for the design of vaccines against infectious diseases. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis. 2014;19:1–5. https://doi.org/10.1016/j.ijid.2013.09.023.

46.

Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, et al. Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. 2016;6:39475. https://doi.org/10.1038/srep39475.CrossRefPubMedPubMedCentral

47.

Carrasco YR, Batista FD. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity. 2007;27(1):160–71. https://doi.org/10.1016/j.immuni.2007.06.007.CrossRefPubMed

48.

Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature. 2007;450(7166):110–4. https://doi.org/10.1038/nature06287.CrossRefPubMed

49.

Gray EE, Cyster JG. Lymph node macrophages. J Innate Immun. 2012;4(5–6):424–36. https://doi.org/10.1159/000337007.CrossRefPubMedPubMedCentral

50.

Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM, van Amerongen G, et al. Modified vaccinia virus Ankara preferentially targets antigen presenting cells in vitro, ex vivo and in vivo. Sci Rep. 2017;7(1):8580. https://doi.org/10.1038/s41598-017-08719-y. CrossRefPubMedPubMedCentral

Title: Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice
Authors: Sofia E. Magnusson
Arwen F. Altenburg
Karin Lövgren Bengtsson
Fons Bosman
Rory D. de Vries
Guus F. Rimmelzwaan
Linda Stertman
Publication date: 01-04-2018
Publisher: Springer US
Published in: Immunologic Research / Issue 2/2018
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-018-8991-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates

Impaired natural killer cell subset phenotypes in human obesity

The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages

Phagocytosis and oxycytosis: two arms of human innate immunity

Chronic graft-specific cell-mediated immune response toward candidate xenogeneic biomaterial

Pemphigus group: overview, epidemiology, mortality, and comorbidities